As part of the agreement, DHK plans to offer Arrayit genomic testing services by extending national network of 800 American Medical Center (AMC) facilities and include medical doctors, nurses, pharmacists and other trained personnel in future.
Arrayit’s patented and proprietary Variation Identification Platform (VIP) microarray technology and blood card collection procedure will be used by both the companies to provide genomic testing information to the Indian population.
Over the next three years, DHK estimates the sale of genomic tests to be 25,000, 50,000 and 100,000 respectively, with $16.8m in cumulative revenue to Arrayit.
Arrayit Corporation CEO Rene Schena said, "The Arrayit-DHK partnership gives us the testing and clinical infrastructure required to improve healthcare in India, enabling our citizens to live happier, longer and more productive lives."